A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists—widely used in blockbuster ...

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

GLP-1RA medications in preadolescents and adolescents were concentrated among those with diabetes, obesity, mood disorders, and anxiety.

Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are ...